Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks
Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed
Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1% between 2021 and 2026
Chris Bunka, Lexaria’s CEO, has lauded the company’s exceptional discovery, which demonstrates the ability of the patented DehydraTECH-processed CBD to lower blood pressure in the patient population

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track for its upcoming submission of an Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial, dubbed HYPER-H23-1. The study, entitled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” looks to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM)-processed CBD in hypertensive patients (https://cnw.fm/8q5JV).

This study builds on five previous human clinical studies conducted from 2018 to 2022, which will be integral to the successful filing and review of the planned IND submission. Most notably, the studies, which involved 134 healthy and hypertensive persons, evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens. In addition, the studies also showed zero serious adverse events, evidencing DehydraTECH-CBD’s potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.

Work that is mainly under Lexaria’s control was completed earlier this year. This included batch manufacturing of DehydraTECH-CBD and placebo materials necessary for the application. However, work outside of Lexaria’s control remains delayed. This includes the provision of required documentation by a materials supplier and stability testing of the material. As such, Lexaria cannot yet submit the IND package to the FDA until the delays have been addressed, although progress is still being made.

In 2021, the global cardiovascular drugs market was estimated at $146.51 billion. By 2026, the market is expected to be valued at $173.48 billion, posting a CAGR of 3.1% (https://cnw.fm/ry230). Lexaria looks to capitalize on this growth while carving a decent market share. The IND application with the FDA will be integral to the company realizing this goal and bringing relief to the many people living with cardiovascular conditions.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/f76N9).

So far, Lexaria is aware of only a handful of other published research studies that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing. However, it notes that none have succeeded in achieving this, proving DehydraTECH-CBD’s superior power to reduce blood pressure over other oral CBD formulations.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Data Shows Border Sales Boosting Retailers’ Earnings in US

Marijuana sales crossing state lines have proven to be a lucrative source of revenue for retailers in the United States, and recent data suggests that a similar trend is emerging along international borders, particularly with Mexico. Insights gathered from various sources, including LeafLink, quarterly reports, state agencies and interviews with marijuana companies, support this observation.

LeafLink’s analysis of numerous ZIP codes found that when new recreational marijuana markets open, retailers near state borders tend to increase their inventory orders significantly compared to those located further inland. Over the past three years, wholesale cannabis product purchases by border stores surged by 140% after the introduction of recreational sales. In contrast, retailers situated in more interior regions increased their purchases by only 80%.

Several factors contribute to these trends, with neighboring state marijuana regulations playing a significant role. For example, Illinois retailers near Wisconsin continue to attract Wisconsinites even after four years of recreational sales in Illinois because marijuana possession remains illegal in Wisconsin.

Additionally, varying retail sales taxes play a part. Operators in the St. Louis area are witnessing an influx of shoppers from southern Illinois, where marijuana taxes are triple the rate of Missouri’s.

Missouri’s recent launch of adult-use sales has created a ripple effect in the Midwest, as it borders eight states, with Illinois being the sole state offering recreational marijuana sales. Missouri’s low 6% retail tax on recreational marijuana purchases attracts Illinois consumers, resulting in significant foot traffic across the Mississippi River.

The impact extends to the wholesale market, with wholesale purchases per store in the Kansas City, Missouri, market increasing by 406% after the launch of recreational sales, according to LeafLink data. Similarly, in the St. Louis market, wholesale purchases per store increased by nearly 57%.

In Maryland, which recently entered the recreational cannabis market, retailers along the state’s borders are experiencing increased demand, with some doubling their orders to meet customer needs. Wholesale product orders increased by 115% in Elkton, near the Delaware border, while in the Germantown/Rockville area, monthly wholesale purchases rose by about 42% since recreational sales began.

Across the U.S.-Mexico border, commercial ties run deep, with residents often crossing freely between Sunland Park, El Paso and Juarez for various purposes, including shopping for regulated marijuana. Other border communities, including Hobbs and Clovis, are also witnessing strong sales, indicating that Texans and some Mexicans are crossing the border to purchase marijuana from New Mexico retailers.

It is highly likely that as cannabis retailers along borders see increased sales, other ancillary businesses such as Innovative Industrial Properties Inc. (NYSE: IIPR) may also be benefiting from this boom as demand for their products and services rises.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Maryland Sells Record-Setting $92M Cannabis During Second Month of Recreational Marijuana Sales

Maryland’s marijuana market achieved another milestone last month, with retailers notching almost $92 million in sales, marking the state’s second month of recreational cannabis sales. This surge represents a significant leap from July’s $87 million, illustrating the transformative impact of expanding cannabis access beyond the medical sector, more than doubling prior sales figures.

Data recently released by the state’s cannabis regulator, MCA, indicates that legal dispensaries tallied sales exceeding $91.7 million. Smokeable flower sales were in the lead at $55.1 million, followed by concentrates at $24.7 million, while infused edibles and nonedibles contributed $6.2 million and $5.2 million, respectively. Trim or shake products brought in $512,991, with marijuana plants contributing $9,588.

July saw a surge in marijuana sales, coinciding with the enactment of a law allowing the state’s medical stores to serve all adults aged 21 years and older. The opening weekend of this transition resulted in an impressive $10 million in cannabis product sales.

Multistate operators (MSOs) have emerged as prominent players in Maryland’s cannabis market, with companies such as Ascend, GTI, Verona and Curaleaf reporting the highest sales figures for the past month.

Later this year, Maryland officials will start taking applications for social-justice cannabis company licenses. The Social Equity Verification Portal, which MCA unveiled last week, will start letting potential applicants determine whether they qualify for the new licenses this week. Equity candidates will be the only ones eligible for the initial round of new cannabis grower, processor, and store licenses.

Maryland levies a 9% sales tax on cannabis for adult use; medical sales are excluded. This indicates that the policy change has already resulted in a few million dollars entering the state’s coffers.

A prohibitionist organization, Smart Approaches to Marijuana, has criticized the state’s management of tax collection. The group alleges that the state’s Office of the Comptroller was actively working to defend banks that were breaking the law.

The accusation was made following the publication of remarks made by Rob Scheerer, director of the Revenue Administration Division of the Maryland Office of the Comptroller, during a Maryland Association of Counties conference last month. Scheerer stated that to safeguard banks, the term “cannabis” could not be used on tax returns, instead employing the term “a sale subject to the 9% rate under SB516 of 2023.”

Both the Office of the Comptroller and Wells Fargo, its banking partner, have asserted that they adhere to the law.

The surging sales in Maryland suggest that the companies operating within that market could see the kind of success that enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) have enjoyed in the markets in which they operate.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Key Senate Committee Chair Promises to Advance Cannabis Banking Bill

The chairman of a key Senate committee has revealed that he discussed the possibility of advancing bipartisan cannabis banking legislation within the next six weeks with Senate Majority Leader Chuck Schumer. During a recent interview with Punchbowl News, Senate Banking Committee chair Sherrod Brown said that he talked to Schumer about moving the Secure and Fair Enforcement (SAFE) Banking Act alongside several other major bills within the next one and a half months.

Cannabis banking has been a contentious issue since states began legalizing medical and recreational cannabis in the United States nearly two decades ago. Although dozens of states now have legal cannabis programs, federal law still classifies marijuana as a Schedule I drug with no medical application. As a result of federal prohibition, licensed cannabis operators find it nigh impossible to access critical financial services such as banking, cashless payments, capital and financial aid.

This forces cannabis businesses to operate on a mostly cash-only basis and puts these businesses at significant risk of violent robberies, something that has been occurring in recent months with increasing frequency. The SAFE Banking Act was introduced to address the lack of access to financial services in America’s multibillion-dollar cannabis industry.

In a recent floor speech and in a letter to fellow lawmakers, Schumer said providing the cannabis industry with access to banking is a priority. He noted that although “making progress on cannabis” via banking legislation was a legislative priority, the legislation wouldn’t progress on the Senate floor without bipartisan support on cannabis reform and related issues, including capping insulin prices and competing with China on the global scale. Additionally, spending legislation will take up a lot of the Senators’ time in the next few weeks, likely reducing the time they have to discuss cannabis banking.

One key section of the SAFE Banking Act (Section 10) has also been subject to intense debate among lawmakers in recent months and even prevented the measure from passing during the summer legislative session.

In late July, Schumer said lawmakers having bipartisan negotiations over the SAFE Banking Act were “making good progress.” The Senate Majority leader reportedly told a lobbyist at the time that Senate lawmakers were working on cannabis banking. He had previously stated that he wished to address marijuana banking reform during the summer session but constant debate over sections of the cannabis banking bill have kept the measure from advancing until the end of the session.

The marijuana industry and its leading entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) have heard such promises before and are unlikely to get too excited by these new pronouncements until actual banking reform is enacted at the federal level.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — NORML Says Rescheduling Cannabis Not Enough

Almost a year after the President Biden administration initiated the process urging the Department of Health and Human Services (HSS) to swiftly evaluate the federal scheduling of marijuana, HHS Secretary Xavier Becerra has affirmed the agency’s recommendation to reclassify cannabis from a Schedule I drug to a lower classification. Although the specific details of the HHS recommendation remain undisclosed, recent Bloomberg News reports indicate that the department advocates moving cannabis to Schedule III within the federal Controlled Substances Act (CSA).

This proposed alteration has garnered praise from certain quarters, particularly within the commercial marijuana industry, as a significant stride forward. Conversely, entities such as NORML have adopted a more measured stance. NORML asserts that there are three key reasons why cannabis ought to be descheduled rather than rescheduled.

First, moving cannabis to a lower schedule under the CSA continues to exaggerate the plant’s purported safety risks in comparison to other controlled drugs, including benzodiazepines (classified as Schedule IV), ketamine and anabolic steroids (presently under Schedule III), or alcohol, which remains unscheduled.

Secondly, moving marijuana to Schedule III deviates from cultural and public consensus. Americans do not wish to equate cannabis with heroin, as it currently stands, but they also oppose its association with Schedule III substances such as ketamine, which can only be legally possessed with a physician’s prescription.

Most crucially, this proposed alteration doesn’t do much to reconcile the growing disparity between federal and state-legal cannabis legislation. If the administration reclassifies cannabis as a Schedule III substance, all state laws currently in conflict with federal-level legislation will persist in their conflict.

Conversely, NORML has consistently advocated for the complete descheduling of cannabis, effectively removing it from the CSA. This approach would empower states, rather than the federal government, to regulate cannabis according to their preferences without violating federal legislation. In a NORML blog post addressing this matter, Paul Armentano, NORML deputy director, expressed his ongoing efforts in promoting NORML’s descheduling initiative to numerous mainstream media channels, including PBS, UPI, the Washington Post and the Associated Press, thereby reaching millions of individuals.

During one of his appearances on CNN, Armentano stated that alcohol and tobacco are conspicuously absent from the CSA, yet they are widely acknowledged to pose significantly greater health hazards than cannabis. He thus argued that cannabis should receive the same treatment when it comes to federal scheduling.

NORML positions itself as a grassroots organization championing freedom and civil liberties while advocating for the interests of responsible cannabis consumers and remaining committed to advancing the case for sensible marijuana policies, including descheduling.

Leading marijuana companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are likely to follow the events in Washington, D.C., until a final decision on marijuana’s current status under the CSA is announced by the DEA.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks — CBDWire to Expand Reach of Green Label Expo & Green Label Summit Las Vegas 2023

CBDWire, a specialized communications platform for the CBD sector and one of the 60+ brands within the InvestorBrandNetwork (“IBN”), today announced its collaboration with the Jotia Group to serve as the media sponsor and official newswire for the highly anticipated Green Label Expo Las Vegas and Green Label Summit. These distinctive, trailblazing cannabis trade shows allow exhibitors to provide live product demonstrations to attendees and are scheduled to take place at the Nuwu Dispensary in Las Vegas on Oct. 31 – Nov. 1, 2023. IBN and CBDWire will leverage a comprehensive range of solutions to amplify recognition for participating companies, breakthrough products and conference attendees, with a view to enhance visibility among investors, journalists, consumers, and the broader public. CBDWire will further expand article reach via syndication across 5,000+ outlets and feature the conference on dedicated event pages. “We are very pleased to be working with IBN and CBDWire towards improving outreach for the Summit and Expo in October,” said JR Richard, event director of the Green Label Series. “With specific expertise in the CBD space, CBDWire will elevate the status of the expo and boost our messaging while generating interest beyond traditional target markets through the latest social media strategies. We look forward to continuing this collaboration in the long run.”

To view the full press release, visit https://cnw.fm/EsltE

About CBDWire

CBDWire (“CBDW”) is a multilayered financial news and publishing company leveraging an innovative, CBD-focused approach to social media management, news distribution and press release enhancement. Backed by a proven team of writers and content creators, CBDW aims to effectively introduce public and private companies working in the CBD space to prospective investors, consumers and industry news outlets. The newswire service’s dissemination network currently spans over 5,000 downstream distribution points, allowing companies to cut through the noise and reach targeted audiences with carefully crafted messages.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which have generated more than $20 million in revenue in each of the last two years; BlueSky products range from full-spectrum oils to edible goods, gummies, topicals and beauty products. As part of the BlueSky acquisition, BlueSky shareholders will receive 3.5 million shares of LSDI stock along with annual earn-out payments based on a multiple of annual EBITDA in each of the next five years. LSDI also recently announced the planned acquisition of all High Times IP and brand assets.

The company noted that once it closes on both the High Times and BlueSky Wellness transactions, it anticipates having an estimated 25 million shares issued and outstanding with the two transactions together projected to add a minimum of $30 million of revenue and $10 million of EBITDA for the first 12-month period after closing. “The addition of the BlueSky portfolio and its team allows us to capitalize on revenue opportunities,” said Lucy Scientific Discovery CEO Richard Nanula in the press release. “Coupled with our High Times acquisition, this strategically positions us for substantial near and long-term growth. This acquisition is a testament to our commitment to expand and grow our business, adding revenue that diversifies our company and should deliver significant value to our Lucy Scientific shareholders.”

To view the full press release, visit https://cnw.fm/lUGuu

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a NASDAQ company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s license granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://cnw.fm/LSDI

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Poll Suggests Most Ohio Voters Favor Legalizing Marijuana

Results from a recently released poll show that most of the voters in Ohio are in favor of a recreational cannabis legalization measure that is set to appear on ballots in November. The poll, which was conducted by Fallon Research, determined that 59% of voters in the state supported the measure to legalize marijuana for individuals 21 years of age and above. Of this number, 68% were Democrats while 62% were independent voters.

The measure qualified for the ballot in August and has garnered support from individuals of different age groups, with the poll finding that more than 65% of adults aged 18 to 44 planned to vote for the measure. The poll showed that 62% of those aged 45 to 64 and 46% of those aged 65 and above also revealed that they planned to vote for the initiative. The poll also found that 9% of voters were on the fence regarding the initiative while another 32% were against the resolution.

While almost 50% of Republicans in the state revealed that they planned to vote to legalize cannabis in the state of Ohio, 46% of voters in the same party admitted that they were opposed to this change. And with regard to racial grouping, 71% of Black voters in the state voiced their support for the bid to legalize marijuana, with 63% of voters of other races and 58% of white voters holding the same opinion.

If the resolution is approved, individuals aged 21 and above would be allowed to possess no more than 2.5 ounces of cannabis and no more than 15g of marijuana concentrates. The resolution would also legalize the cultivation of cannabis for personal use, with adults being permitted to cultivate up to six plants. Houses with more than a single adult would be allowed to grow 12 plants in total.

The initiative would also establish a new agency, called the Division of Cannabis Control, to regulate the commercial production and sale of marijuana products. This state agency would also be tasked with licensing, regulating, penalizing and investigating adult-use cannabis testing labs, adult-use marijuana operators and parties in need of licenses.

In addition, all marijuana products would be subjected to a 10% tax, which would be allocated to substance misuse treatment programs, a social-equity and employment program, and administrative costs of regulation.

Voters are set to go to the polls on Nov. 7, 2023. If the measure is approved, Ohio will join the 23 other states that have already legalized recreational use cannabis.

If voters pass the cannabis legalization measure and a legal cannabis market is finally launched in the state, many opportunities could be created for entrepreneurs, and the kind of success being enjoyed by companies such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) could be emulated by the companies that serve Ohio residents.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Spokesperson Says Biden Supports Medical Marijuana as Cannabis Scheduling Review Progresses

President Joe Biden’s stance on the medical use of marijuana has been unequivocal, as affirmed by the White House amid an ongoing federal review of cannabis scheduling. In a recent press briefing, Karine Jean-Pierre, White House press secretary, addressed inquiries regarding the potential ramifications of reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

The U.S. Department of Health and Human Services (HHS) recently recommended this reclassification to the U.S. Drug Enforcement Administration (DEA).

Jean-Pierre, exercising caution, refrained from preempting the process. She emphasized, “I don’t want to anticipate events; I’ve encountered this query previously.” She clarified, “Let me be clear: The president directed both the HHS secretary and the attorney general to initiate the administrative evaluation of marijuana’s scheduling, as you have outlined.”

Nonetheless, Jean-Pierre reiterated the president’s endorsement of federal cannabis reform, particularly concerning medical marijuana. Biden’s support for cannabis reform has not been unwavering. During his tenure as a senator, he championed legislation that intensified the war on drugs.

Should the DEA concur with HHS’s Schedule III recommendation, it would signify a pivotal shift in federal cannabis policy. The reclassification would acknowledge that cannabis possesses low potential for abuse and offers medical utility. However, it would not endorse existing state-level medical marijuana programs. Nevertheless, it would facilitate expanded research into the plant and have substantial implications for the marijuana industry.

Bipartisan congressional representatives have applauded the health agency’s recommendation, viewing it as a significant stride toward federal legalization. Some have even claimed credit for this advancement, citing their years of advocacy for marijuana reform.

Despite the enthusiasm surrounding this development, the scheduling decision remains tentative. The DEA has stated that it will initiate its review, factoring in findings from the FDA. Ultimately, the DEA retains the authority to decide on the reclassification to Schedule III.

From a political perspective, moving cannabis from Schedule I to III would allow the president to assert his role in achieving a substantial reform, facilitating an administrative evaluation more than half a century after cannabis was categorized as the most restrictive substance during the government’s war on drugs. However, it would not fulfill his campaign promise to decriminalize cannabis.

The reform could also invigorate momentum for congressional initiatives aimed at altering federal marijuana laws, such as the cannabis banking reform bill listed among the legislative priorities of Chuck Schumer, the Senate Majority Leader, according to a recent Dear Colleague letter.

As broader cannabis policy reforms take shape, industry actors such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) could be poised for explosive growth as the market is opened across the country.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) to Acquire BlueSky Wellness Inc. in All-Stock Transaction

Lucy Scientific Discovery (NASDAQ: LSDI) is the leader in the psychotropic industry, which recently celebrated the acquisition of the intellectual property of High Times, the most iconic brand in the cannabis industry. Today the company announced an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands, expanding Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities. BlueSky Wellness is a portfolio of plant-based brands including Keoni, Keoni Sport, Blush Wellness and AMMA Healing. It has generated over $20 million in each of the last two years through its e-commerce brands that are well positioned with a collection of products ranging from full-spectrum oils to edible goods that complement High Times’ products and platforms.

“The addition of the BlueSky portfolio and its team allows us to capitalize on revenue opportunities,” Richard Nanula, CEO of Lucy Scientific Discovery, said in the press release. “Coupled with our High Times acquisition, this strategically positions us for substantial near and long-term growth. This acquisition is a testament to our commitment to expand and grow our business, adding revenue that diversifies our company and should deliver significant value to our Lucy Scientific shareholders.”

To view the full press release, visit https://cnw.fm/JMved

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://cnw.fm/LSDI

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com